Safety and Efficacy of Atezolizumab, Obinutuzumab and Venetoclax Combination for Relapsed/Refractory Non-Hodgkin Lymphomas: Results From the Safety-Run of a Lysa Study
Hematological Oncology - United Kingdom
doi 10.1002/hon.144_2630
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley